Latigo Biotherapeutics, Inc. IPO
listed
| Exchange | Nasdaq |
| Ticker | LTGO |
| Price range | $16–18 |
| IPO price | $18 |
| Deal size | $346m |
| First-day close | $18.25 (+1.4%) |
| Priced | 6 Aug 2026 |
| First trading day | 7 Aug 2026 |
| First filing seen | 3 Aug 2026 |
| Industry | Pharmaceutical Preparations |
| Headquarters | Thousand Oaks, CA |
| Incorporated in | DE |
Upsized to 19.2 million shares from 16 million; priced at the high end of the $16-$18 range. Non-opioid pain biotech. Source does not say if size includes over-allotment.
SEC filings
| Form | What it is | Filed |
|---|---|---|
| S-1/A | Amended registration statement | 4 Aug 2026 |
| S-1/A | Amended registration statement | 3 Aug 2026 |
Deal terms: Renaissance Capital ↗ · Filings: SEC EDGAR ↗
This page reports public filings and reported deal terms. It is not a recommendation to buy, sell or apply.